A method for improving the therapeutic effect of CAR-NK cells
By designing CAR-NK cells targeting CD19 and screening, the problems of CAR-NK cells in tumor treatment are solved, and the effect of significantly improving tumor killing activity is achieved, showing stronger and better Rapid tumor killing ability.
Patent Information
- Application Number
- CN202410305579.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-18
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-03-18
AI Technical Summary
CAR-NK cells have insufficient durability in tumor treatment, immunosuppression, poor effect in tumor microenvironment and the impact of freeze-thawing process on survival, resulting in low killing efficiency, limiting their widespread application.
By designing CAR-NK cells targeting CD19, including the scFv, CD8 hinge, CD8 transmembrane region and CD3ζ combined with 4-1BB signaling domain that specifically target CD19, and screening using EGFP fluorescent labeling, using lentiviral vector transgenicity Staining and multiple rounds of parallel culture selection process were screened for CAR-NK cells with significant tumor killing effects.
It significantly improved the tumor killing effect of CAR-NK cells, and it quickly caused the target cell membrane to rupture and kill after contacting the target cell, with a killing rate of more than 60%, and the average killing time was only 20 minutes. The genome sequencing of cloned cells showed that perforin gene mutations support their high efficiency. Can kill.
Smart Images

Figure SMS_1 
Figure SMS_9 
Figure SMS_10
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a method for improving the therapeutic effect of CAR-NK cells. Background Art
[0002] Chimeric antigen receptor (CAR)-modified T cells have revolutionized the field of cell therapy for cancer treatment and are one of the most important breakthroughs in tumor treatment in recent years. Currently, a number of CAR-T products have been approved for marketing, bringing significant clinical benefits to cancer patients. Although this strategy has been shown to have a very significant clinical effect on B-cell malignancies, its application still has certain limitations: on the one hand, it produces cytokine release syndrome (CRS) and immune effector cell-related neurotoxicity syndrome; on the other hand, allogeneic T cells (even if HLA matching) may lead to the risk of graft-versus-host disease (GVHD). In addition, the relatively long preparation cycle also restricts the further widespread application of CAR-T cells. Corresponding to T cells, NK cells (natural-killer cells) account for 5% to 10% of peripheral blood lymphocytes and are an important part of the innate immune system. They play a key role in the first-line defense against pathogens and cancer cells. Current studies have shown that CAR-modified NK cells may overcome the above-mentioned shortcomings of CAR-T cells, show significant anti-tumor effects, and have the potential to be prepared as "off-the-shelf" products. Therefore, CAR-NK cells show broad prospects in tumor immunotherapy.
[0003] NK cells have a specific killing effect on transformed or other abnormal cells in the body. In order to recognize and protect healthy cells, NK cells mainly rely on inhibitory receptors (such as killer cell immunoglobulin-like receptors KIRs and NKG2A) to bind to the class I molecules of the tissue compatibility complex (MHC) expressed on normal cells, and act as a safety switch to inhibit NK cell toxicity. In clinical trials, NK cells do not induce GVHD like T cells, which has opened up new avenues for their widespread use in allogeneic environments and the production of ready-made cell therapy products. Compared with CAR-T cells, CAR-NK cells hardly cause CRS and neurotoxicity. Moreover, CAR-NK cells used in clinical practice are rich in sources and can be produced from peripheral blood (PB), umbilical cord blood (CB), human embryonic stem cells (HESC), induced pluripotent stem cells (IPSC), and NK-92 cell lines.
[0004] The basic structure of the functional CAR molecule expressed on NK cells includes an antigen recognition domain composed of a single-chain variable fragment (scFv), an extracellular hinge domain, a transmembrane domain, and an intracellular activation domain. The scFv consists of heavy and light chains bound to a linker, which determines the specificity of the CAR. The hinge region connects the tumor antigen binding domain to the transmembrane region, ensuring the stability of the CAR and providing flexibility for easy access to the target protein. The transmembrane region connects the extracellular and intracellular CAR domains, docks the CAR to the cell membrane and transduces the activation signal into an intracellular activation signal. The number of intracellular activation domains determines the generation of CAR, and various combinations of activation domains are used to produce anti-tumor responses. Depending on the intracellular region, CAR-NK has developed to the fourth generation. The first generation of CARs consists of a basic structure with a signaling region; the second generation of CARs contains additional co-stimulatory domains, such as CD28 or 4-1BB; the third generation of CARs has multiple co-stimulatory domains, including members of the immunoglobulin superfamily (CD28 and ICOS), members of the TNF receptor superfamily (4-1BB, CD27, OX40 and CD40), and others such as CD40L and TLRs. These CAR-NK modifications are aimed at improving the proliferation, persistence and anti-tumor ability of CAR-NK cells. So far, the role of CAR modification in improving the efficacy of CAR-NK still needs the support of large-scale clinical trials.
[0005] CAR-NK cells have good clinical safety, but there are still some obstacles in their clinical application. (1) NK cells lack persistence in vivo. Although the addition of exogenous cytokines can enhance the proliferation and persistence of NK cells, it can also cause individual adverse toxicity and immunosuppression of other immune groups. (2) Currently, CAR-NK has achieved good therapeutic effects in the treatment of hematological tumors, but due to the immunosuppression of the tumor microenvironment, the effect is poor in solid tumors. Some studies have attempted to combine CAR engineering with checkpoint deletion as an effective method to enhance the anti-tumor activity of NK cells. (3) Rapid homing to the tumor bed is crucial to the efficacy of adoptive cell therapy, which is regulated by the complex interaction between chemokines secreted by NK cells and chemokines secreted by tumor cells. At present, some studies have tested some new strategies to increase the migration of NK cells to tumor sites in mouse models, but they still need to be verified in clinical trials. (4) The freezing and thawing process changes the survival rate of NK cells and significantly reduces cytotoxicity. In general, the killing efficiency of various modified CAR-NK against tumors is generally not high (see Table 1 for details). Significantly improving the tumor killing activity of CAR-NK is the key to breaking through the existing bottleneck and realizing its widespread application.
[0006] Table 1 Summary of CAR-NK tumor killing activity in existing studies
[0007]
[0008] Note: E: effector cell; T: target cell; E: ratio of T effector cells to target cells.
[0009] Compared with CAR-T cells, CAR-NK cells have their own unique advantages and are currently a key hotspot in the field of tumor cell therapy, but they also face challenges. The key to breaking the current bottleneck is to significantly improve their anti-tumor activity. Due to the complexity of the NK cell regulatory network, it is difficult to obtain a stable ideal phenotype by relying solely on rational design. It is urgent to introduce new research theories and systems to develop a "new generation" of CAR-NK cell products on this basis, thereby bringing new breakthroughs in tumor treatment. Summary of the invention
[0010] The purpose of the first aspect of the present invention is to provide a CAR-NK cell.
[0011] The purpose of the second aspect of the present invention is to provide a method for preparing the CAR-NK cells of the first aspect of the present invention.
[0012] The purpose of the third aspect of the present invention is to provide the use of the CAR-NK cells of the first aspect of the present invention and / or the preparation method of the second aspect of the present invention in the preparation of drugs for treating and / or preventing diseases.
[0013] The purpose of the fourth aspect of the present invention is to provide the use of the CAR-NK cells of the first aspect of the present invention and / or the preparation method of the second aspect of the present invention in lysing tumor cells or preparing products of lysed tumor cells.
[0014] The fifth aspect of the present invention aims to provide a product.
[0015] In order to achieve the above object, the technical solution adopted by the present invention is:
[0016] In a first aspect of the present invention, a CAR-NK cell is provided, wherein the CAR-NK cell expresses a CAR targeting CD19 on the surface of NK cells, and the structure of the CAR includes a scFv specifically targeting CD19, a hinge from CD8, a transmembrane region from CD8, and a CD3ζ combined with a 4-1BB signaling domain.
[0017] In some embodiments of the present invention, the nucleotide sequence of the scFv specifically targeting CD19 is shown in SEQ ID NO: 1.
[0018] In some embodiments of the present invention, the nucleotide sequence of the hinge from CD8 is shown in SEQ ID NO:2.
[0019] In some embodiments of the present invention, the nucleotide sequence from the CD8 transmembrane region is shown as SEQ ID NO:3.
[0020] In some embodiments of the present invention, the nucleotide sequence of the CD3ζ combined with 4-1BB signaling domain is shown in SEQ ID NO:4.
[0021] In some embodiments of the present invention, the structure of the CAR also includes an EGFP fluorescent marker.
[0022] In some embodiments of the present invention, the nucleotide sequence of the EGFP fluorescent marker is shown as SEQ ID NO:5.
[0023] The second aspect of the present invention provides a method for preparing the CAR-NK cells of the first aspect of the present invention, comprising the step of transfecting NK cells with a vector expressing the CAR.
[0024] NK cell lines (taking the NK-92 cell line, which is currently the most widely used in clinical applications, as an example) accumulate a large number of genetic mutations during isolation and culture, and are therefore a cell population composed of a large number of NK cells with significant differences in killing ability, which seriously affects the overall killing ability of NK cells and the stability of the killing effect. In order to screen CAR-NK cells with significantly enhanced tumor killing effects, the present invention refers to the classic Luria-Delbruck experiment, and co-cultures CAR-NK cells with EGFP green fluorescence and Raji cells with DsRed red fluorescence, and undergoes multiple rounds of "parallel culture → selection → amplification → parallel culture" process.
[0025] In some embodiments of the present invention, the preparation method specifically comprises:
[0026] (1) Using a lentiviral vector to stably transfect the sequence of the CD19-targeting CAR into NK cells, cell;
[0027] (2) Screening for CAR-NK cells with significant tumor killing effects:
[0028] a) The obtained The cells were co-cultured with Raji cells with DsRed red fluorescence, and the cells with the lowest DsRed red fluorescence signal value were selected;
[0029] b) Expansion training;
[0030] c) co-culture with cells with DsRed red fluorescence, and select cells with the lowest DsRed red fluorescence signal value;
[0031] d) repeating steps b) to c) for n times to obtain CAR-NK cells with significant tumor killing effect;
[0032] The screening process takes 6 to 12 months.
[0033] In some embodiments of the present invention, the co-cultivation time is 3 to 5 hours.
[0034] In some preferred embodiments of the present invention, the co-cultivation time is 3 to 4 hours.
[0035] In some preferred embodiments of the present invention, the co-cultivation time is 4 hours.
[0036] In some embodiments of the present invention, the The cell number ratio of cells to Raji cells is 1:(1~2).
[0037] In some preferred embodiments of the present invention, the The cell number ratio of cells to Raji cells was 1:1.
[0038] In some embodiments of the present invention, the cells with DsRed red fluorescence described in c) include any one of Raji cells, WIL2-S cells, SU-DHL-10 cells, DOHH2 cells, BJAB cells, A20 cells, SU-DHL-4 cells, P30 / OHK cells, P116 cells, MUTZ-3 cells, SUPB15 cells, SNK6 cells, SK-MEL-28 cells, C8161 cells, and RPMI-7951 cells.
[0039] The third aspect of the present invention provides use of the CAR-NK cells of the first aspect of the present invention and / or the preparation method of the second aspect of the present invention in the preparation of drugs for treating and / or preventing diseases.
[0040] In some embodiments of the present invention, the drug comprises an anti-tumor drug.
[0041] In some embodiments of the present invention, the anti-tumor drug is a drug capable of treating tumors targeting CD19.
[0042] The fourth aspect of the present invention provides the use of the CAR-NK cells of the first aspect of the present invention and / or the preparation method of the second aspect of the present invention in lysing tumor cells or preparing products of lysing tumor cells.
[0043] In some embodiments of the present invention, the product includes drugs and reagents.
[0044] The fifth aspect of the present invention provides a product comprising the CAR-NK cells of the first aspect of the present invention.
[0045] In some embodiments of the present invention, the product includes drugs and reagents.
[0046] In some embodiments of the present invention, the functions of the product include killing or injuring tumor cells and lysing tumor cells.
[0047] The beneficial effects of the present invention are:
[0048] Compared with the CAR-NK cells in the prior art, the CAR-NK cells provided by the present invention exhibit stronger and faster tumor killing effects. Experiments have shown that after the CAR-NK cells come into contact with target cells, they quickly cause the target cell membrane to rupture and the intracellular substances to flow out. The average time for killing tumor cells is only 20 minutes; when the effector-target ratio is 1:5, a killing rate of more than 60% can be achieved. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 This is the screening process for “CAR-NK_Evo” cells.
[0050] Figure 2 is the tumor killing effect of "CAR-NK_Evo" cells; A is the tumor killing effect of "CAR-NK_Evo" cells under different effector-target ratios, B is the evaluation result of the speed and method of "CAR-NK_Evo" cells killing target cells, and C is the evaluation result of "CAR-NK_Evo" cells and Time statistics of cells killing target cells.
[0051] Figure 3 Whole genome sequencing results of “CAR-NK_Evo” cells after isolating single cells and culturing them into clones.
[0052] Figure 4 This is the structure diagram of the PLVX-DsRed-Monomer-N1 plasmid. DETAILED DESCRIPTION
[0053] The present invention will now be described in detail with reference to specific embodiments, but the scope of the present invention is not limited thereto.
[0054] Unless otherwise specified, the materials and reagents used in this example were obtained from commercial sources.
[0055] Example 1
[0056] A method for improving the therapeutic effect of CAR-NK cells, comprising the following steps:
[0057] (1) Construction of CAR-NK cells targeting CD19 derived from NK-92: In the design of CAR-NK, the extracellular region is an optimized scFv (single-chain variable region) (SEQ ID NO: 1) that recognizes CD19, the hinge region (SEQ ID NO: 2) and the transmembrane region (SEQ ID NO: 3) are derived from CD8, and the intracellular region (SEQ ID NO: 4) is a CD3ζ combined with 4-1BB signaling domain, and it also carries EGFP (SEQ ID NO: 5) as a selection marker. The sequence of CAR-CD19 was stably transfected into NK-92 cells through a lentiviral vector, and then the next step of experimental evolution and artificial screening was started. The CAR-NK cells that were not screened and evolved were recorded as cell.
[0058] scFv (single-chain variable region) targeting CD19:
[0059] ATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGACATCCAGATGACACAGACTACATCCTCCCTGTCTGCCTCTCTGGGAGACAGAGTCACCATCAGTTGCAGGGCAAGTCAGGACATTAGTAAATATTTAAATTGGTATCAGCAGAAACCAGATGGAACTGTTAAACTCCTGATCTACCATACATCAAGATTACACTCAGGAGTCCCATCAAGGTTCAGTGGCAGTGGGTCTGGAACAGATTATTCTCTCACCATTAGCAACCTGGAGCAAGAAGATATTGCCACTTACTTTTGCCAACAGGGTAATACGCTTCCGTACACGTTCGGAGGGGGGACTAAGTTGGAAATAACAGGCTCCACCTCTGGATCCGGCAAGCCCGGATCTGGCGAGGGATCCACCAAGGGCGAGGTGAAACTGCAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCGTCACATGCACTGTCTCAGGGGTCTCATTACCCGACTATGGTGTAAGCTGGATTCGCCAGCCTCCACGAAAGGGTCTGGAGTGGCTGGGAGTAATATGGGGTAGTGAAACCACATACTATAATTCAGCTCTCAAATCCAGACTGACCATCATCAAGGACAACTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTGCAAACTGATGACACAGCCATTTACTACTGTGCCAAACATTATTACTACGGTGGTAGCTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCAGCGGCCGCA(SEQ ID NO:1).
[0060] Hinge region from CD8:
[0061] GCGAAGCCCACCACGACGCCAGCGCCGCGACCACCAACACCGGCGCCCACCATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGCCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGAT(SEQ ID NO:2).
[0062] Transmembrane region from CD8:
[0063] ATCTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTATCACCCTTTACTGC(SEQ ID NO:3).
[0064] Intracellular region (CD3ζ combined with 4-1BB signaling domain):
[0065] AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGAGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGC(SEQ ID NO:4).
[0066] EGFP labeling sequence:
[0067] (SEQ ID NO:5).
[0068] (2) Screening CAR-NK cells with significantly enhanced tumor killing effect: Referring to the Luria-Delbruck experiment, CAR-NK cells with EGFP green fluorescence were co-cultured with Raji cells with DsRed red fluorescence, and multiple rounds of "parallel culture → selection → amplification → parallel culture" were carried out. The specific steps include: 1) 10 6CAR-NK cells and Raji cells (purchased from ATCC, https: / / www.atcc.org / products / ccl-86) were mixed evenly in a 1:1 ratio; 2) the cells were evenly divided into 384-well plates and cultured in parallel for 4 hours; 3) the DsRed red fluorescence signal value in each well was analyzed using a high-content living cell observation platform, and the well with the lowest signal value was selected, which may contain CAR-NK cells with strong killing activity; 4) the CAR-NK cells in the well with the lowest DsRed red fluorescence signal value were expanded and cultured to 10 6 , mixed evenly with new Raji cells in a 1:1 ratio, and a new round of screening began; 5) After a long period of screening (about 6 months to 1 year) (i.e., repeated steps 1) to 4), CAR-NK cells with significantly enhanced tumor killing effects were obtained, named "CAR-NK_Evo" cells. The screening process is as follows Figure 1 shown.
[0069] Example 2
[0070] This example is used to analyze the mode of action of "CAR-NK_Evo" cells, and the specific process is as follows:
[0071] The process of evaluating the killing effect of CAR-NK cells using a high-content analysis platform:
[0072] (1) Preparation for killing experiment (using Raji cells as an example of target cells):
[0073] 1) Cells: CAR-CD19-GFP-NK92 ( CAR-NK_Evo); Raji cells.
[0074] 2) Reagents: VIVO+IL-2 (200 U / mL)+1% P / S complete culture medium; Trypan blue.
[0075] 3) Well plate: six-well plate (Costar, 3516).
[0076] (2) Preparation and collection of target cells:
[0077] 1) PLVX-DsRed-Monomer-N1 (structure diagram see Figure 4 ) lentiviral packaging;
[0078] 2) PLVX-DsRed-Monomer-N1 lentivirus was used to transfect Raji, and stable strains of PLVX-DsRed-Raji were screened using puromycin;
[0079] 3) Mix the Raji cells from one T25 bottle, take 5 mL, centrifuge at 1000 rpm for 5 min, and remove the supernatant;
[0080] 4) After centrifugation of the Raji cells, add 1 mL of VIVO + IL-2 (200 U / mL) + 1% P / S complete medium to resuspend the cells, transfer them to a 1.5 ml EP tube, and count the cells;
[0081] 5) 20 μL cell suspension + 20 μL trypan blue (i.e. 2-fold dilution), count twice.
[0082] (3) Preparation and collection of effector cells:
[0083] 1) Mix the NK92 cultured in the T25 bottle, collect 5 mL into a 15 mL centrifuge tube, centrifuge at 1000 rpm for 5 min, and remove the supernatant;
[0084] 2) Add 1 mL VIVO + IL-2 (200 U / mL) + 1% P / S medium to resuspend the cells, transfer the cell suspension to a 1.5 mL EP tube, and then count the cells; 20 μL cell suspension + 20 μL trypan blue (i.e. 2-fold dilution), count twice;
[0085] 3) Take 10 5 Target / 10 5 Effector cells calculate the amount of effector cells and target cells added;
[0086] 4) The overall system is shown in Table 2 below.
[0087] Table 2 Cell status in the total system
[0088]
[0089]
[0090] Take a six-well plate, first add 1 mL of VIVO medium to wet the plate, add target cells to one well first, then add effector cells, and finally add VIVO + IL-2 (200 U / mL) + 1% P / S complete medium.
[0091] 5) Mix the plate gently and place it in an incubator to let it rest.
[0092] 6) Turn on the high-content instrument and set the temperature of the instrument to 37°C, the CO2 switch to 5%, the magnification to 40×, and the time interval to 5 minutes.
[0093] 7) Place the co-cultured cell plate in a high-content instrument and select an appropriate focal length and field of view for dynamic observation.
[0094] The results are as follows Figure 2 As shown in the figure, under different effector-target ratios (ratio of CAR-NK cells to tumor cells), the "CAR-NK_Evo" cells obtained by long-term artificial selection (i.e., the screening process of Example 1) have significantly higher tumor killing effects, and can achieve a killing rate of more than 60% when the effector-target ratio is 1:5 ( Figure 2 A). The speed and method of "CAR-NK_Evo" cells killing target cells were evaluated using the live cell observation platform. The green markers in the figure are NK cells, and the orange markers are target cells (Raji cells). The time is marked in the upper left corner of each frame, and the time when NK cells contact target cells is recorded as time 0. It can be seen from the figure that without selection After the cells come into contact with the target cells, it takes 3 hours for the target cells to lyse and apoptosis. However, after the "CAR-NK_Evo" cells come into contact with the target cells, the target cell membranes rupture and the intracellular substances flow out rapidly. Figure 2 (B) Further statistics of “CAR-NK_Evo” cells and The time it takes for cells to kill target cells. The high-content platform was used to observe and record the time required for each killing event. At least 30 killing events were observed in each group of experiments. Statistics show that when the effector-target ratio was 1:2 and 1:1, respectively, "CAR-NK_Evo" cells can quickly kill target cells. The average time required to kill target cells was about 20 minutes, which is much less than 1:1. The time required for cells (more than 120 minutes) Figure 2 Middle C).
[0095] Example 3
[0096] This example is used to analyze the genome of "CAR-NK_Evo" cells. The "CAR-NK_Evo" cells obtained by screening in Example 1 were separated into single cells and cultured into clones (a total of 4 clones were selected, namely clone #1, clone #2, clone #3 and clone #4), and then whole genome sequencing was performed. Analysis found that multiple clones had mutations in the perforin gene PRF1, including C31Y mutations on clone #1, G45V mutations on clone #2, G71V mutations on clone #3, and C76S mutations on clone #4. Figure 3 For gene sequence comparison, the upper part of the figure shows The sequencing results of the cells, the lower part shows the sequencing results of different "CAR-NK_Evo" cell clones, and the orange area marks the codons where mutations occurred. Since different "CAR-NK_Evo" cell clones carry different mutations, the inventors believe that they have accumulated multiple mutations of independent origin in the perforin gene PRF1.
[0097] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. A CAR-NK cell, wherein the CAR-NK cell is a CAR that targets CD19 expressed on the surface of NK cells, and the structure of the CAR includes a scFv that specifically targets CD19, a hinge from CD8, a transmembrane region from CD8, a CD3ζ combined with a 4-1BB signaling domain, and an EGFP fluorescent marker; the NK cell is a NK-92 cell; The CAR-NK cells are prepared by a preparation method comprising the following steps: (1) using a lentiviral vector to stably transfect the sequence of the CD19-targeting CAR into NK cells to obtain CAR-NK_Naïve cells; (2) Screening for CAR-NK cells with significant tumor killing effects: a) co-culturing the CAR-NK_Naïve cells obtained in step (1) with Raji cells with DsRed red fluorescence, and selecting cells with the lowest DsRed red fluorescence signal value; b) Expansion training; c) Co-culture with cells with DsRed red fluorescence and select cells with the lowest DsRed red fluorescence signal value; d) Repeating steps b) to c) for n times to obtain CAR-NK cells with significant tumor killing effect; The co-culture time is 3-5 hours, and the cell number ratio of the CAR-NK_Naïve cells to the Raji cells is 1:(1-2); The screening process takes 6 to 12 months.
2. The CAR-NK cell according to claim 1, characterized in that The nucleotide sequence of the scFv specifically targeting CD19 is shown in SEQ ID NO:
1.
3. The CAR-NK cell according to claim 1, characterized in that The nucleotide sequence of the hinge from CD8 is shown in SEQ ID NO: 2; and / or, the nucleotide sequence from the transmembrane region of CD8 is shown in SEQ ID NO: 3; and / or, the nucleotide sequence of the CD3ζ combined with the 4-1BB signaling domain is shown in SEQ ID NO:
4.
4. The CAR-NK cell according to any one of claims 1 to 3, characterized in that The nucleotide sequence of the EGFP fluorescent marker is shown in SEQ ID NO:
5.
5. Use of the CAR-NK cell according to any one of claims 1 to 4 in the preparation of a drug for treating and / or preventing a disease, wherein the drug is a drug capable of treating a tumor targeting CD19.
6. Use of the CAR-NK cell according to any one of claims 1 to 4 in the preparation of a product for lysing tumor cells expressing CD19.
7. A product comprising the CAR-NK cell according to any one of claims 1 to 4.
